Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn
P A
PA
D000970:Antineoplastic Agents / Q000627:therapeutic use; D004167:Diphtheria Toxin / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D009182:Mycosis Fungoides / Q000628:therapy; D010166:Palliative Care; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000628:therapy; D012878:Skin Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D000922:Immunotoxins; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins